Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
AbbVie,Risankizumab,Moderate to severe plaque psoriasis - second line biologic,Risankizumab,Options for investment,Community and Hospital,
